Activation of BTAK expression in primary ovarian surface epithelial cells of prophylactic ovaries
暂无分享,去创建一个
Meenakshi Singh | Jinsong Liu | Meenakshi Singh | Gong Yang | D. Rosen | Zhihong Zhang | Jinsong Liu | S. Davidson | Daniel G Rosen | Zhihong Zhang | Susan Davidson | Gong Yang
[1] A. D’Andrea,et al. The Fanconi Anemia/BRCA pathway: new faces in the crowd. , 2005, Genes & development.
[2] D Lowe,et al. Comparison of prophylactic oophorectomy specimens from carriers and noncarriers of a BRCA1 or BRCA2 gene mutation. United Kingdom Coordinating Committee on Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group. , 1999, Journal of the National Cancer Institute.
[3] R. Ozols,et al. Age-dependent morphological alterations of human ovaries from populations with and without BRCA mutations. , 2006, Gynecologic oncology.
[4] J Gil,et al. Ovarian dysplasia in prophylactic oophorectomy specimens , 1999, Cancer.
[5] D. Medina,et al. Centrosome amplification and overexpression of aurora A are early events in rat mammary carcinogenesis. , 2002, Cancer research.
[6] D. F. Easton,et al. The genetics of breast and ovarian cancer. , 1995, British Journal of Cancer.
[7] A. Godwin,et al. Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies. , 1996, Journal of the National Cancer Institute.
[8] C. Deng,et al. Overexpression of aurora kinase A in mouse mammary epithelium induces genetic instability preceding mammary tumor formation , 2006, Oncogene.
[9] S. Sen,et al. Frequent overexpression of STK15/Aurora-A/BTAK and chromosomal instability in tumorigenic cell cultures derived from human ovarian cancer. , 2005, Oncology research.
[10] G. Mills,et al. Cyclin E expression is correlated with tumor progression and predicts a poor prognosis in patients with ovarian carcinoma , 2006, Cancer.
[11] P. Meltzer,et al. Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[12] Nigam H. Shah,et al. Can we identify cellular pathways implicated in cancer using gene expression data? , 2003, Computational Systems Bioinformatics. CSB2003. Proceedings of the 2003 IEEE Bioinformatics Conference. CSB2003.
[13] C. Voelkel-Johnson. An Antibody Against DR4 (TRAIL-R1) in Combination with Doxorubicin Selectively Kills Malignant but not Normal Prostate Cells , 2003, Cancer biology & therapy.
[14] R. Ozols,et al. Loss of surface and cyst epithelial basement membranes and preneoplastic morphologic changes in prophylactic oophorectomies , 2003, Cancer.
[15] A. Venkitaraman,et al. Abnormal Cytokinesis in Cells Deficient in the Breast Cancer Susceptibility Protein BRCA2 , 2004, Science.
[16] T. Ouchi,et al. Cell Cycle Differences in DNA Damage-induced BRCA1 Phosphorylation Affect Its Subcellular Localization* , 2003, The Journal of Biological Chemistry.
[17] H. Lynch,et al. Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds. , 2000, Gynecologic oncology.
[18] A. Godwin,et al. Autonomy of the epithelial phenotype in human ovarian surface epithelium: Changes with neoplastic progression and with a family history of ovarian cancer , 1996, International journal of cancer.
[19] C. Prigent,et al. Aurora kinases, aneuploidy and cancer, a coincidence or a real link? , 2005, Trends in cell biology.
[20] X. Wang,et al. Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. , 1999, Molecular cell.
[21] Domenico Coppola,et al. Activation and overexpression of centrosome kinase BTAK/Aurora-A in human ovarian cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[22] K. Offit,et al. Absence of premalignant histologic, molecular, or cell biologic alterations in prophylactic oophorectomy specimens from BRCA1 heterozygotes , 2000, Cancer.
[23] R. Bast,et al. Use of Ras-transformed human ovarian surface epithelial cells as a model for studying ovarian cancer. , 2006, Methods in enzymology.
[24] H. Saya,et al. Roles of aurora‐A kinase in mitotic entry and G2 checkpoint in mammalian cells , 2002, Genes to cells : devoted to molecular & cellular mechanisms.
[25] D. V. Von Hoff,et al. Targeting aurora2 kinase in oncogenesis: a structural bioinformatics approach to target validation and rational drug design. , 2003, Molecular cancer therapeutics.
[26] Y. Nakamura,et al. Tumour-amplified kinase BTAK is amplified and overexpressed in gastric cancers with possible involvement in aneuploid formation , 2001, British Journal of Cancer.
[27] J. Niloff,et al. Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] M. Kastan,et al. p53 and ATM: cell cycle, cell death, and cancer. , 1997, Advances in cancer research.
[29] P. Leung,et al. Ovarian surface epithelium: biology, endocrinology, and pathology. , 2001, Endocrine reviews.
[30] W. El-Deiry,et al. Repression of BRCA1 through a Feedback Loop Involving p53* , 2000, The Journal of Biological Chemistry.
[31] F. Penault-Llorca,et al. Prophylactic oophorectomy , 2003, Cancer.
[32] B. Rosen,et al. Occult Carcinoma in Prophylactic Oophorectomy Specimens: Prevalence and Association With BRCA Germline Mutation Status , 2001, The American journal of surgical pathology.
[33] Jian Kuang,et al. Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation , 1998, Nature Genetics.
[34] S. Sen,et al. Dynamic association of a tumor amplified kinase, Aurora-A, with the centrosome and mitotic spindle. , 2003, Cell motility and the cytoskeleton.
[35] H. Saya,et al. RNA interference targeting aurora kinase a suppresses tumor growth and enhances the taxane chemosensitivity in human pancreatic cancer cells. , 2005, Cancer research.
[36] P. Kruk,et al. Telomeric instability and reduced proliferative potential in ovarian surface epithelial cells from women with a family history of ovarian cancer. , 1999, Gynecologic oncology.
[37] Brian Schryver,et al. A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers , 1998, The EMBO journal.
[38] H. Saya,et al. Aurora-A and an Interacting Activator, the LIM Protein Ajuba, Are Required for Mitotic Commitment in Human Cells , 2003, Cell.
[39] Thomas Ried,et al. Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation , 1999, Nature Genetics.
[40] Hiroshi Katayama,et al. The Aurora kinases: Role in cell transformation and tumorigenesis , 2003, Cancer and Metastasis Reviews.
[41] B. Weber,et al. BRCA1 signals ARF-dependent stabilization and coactivation of p53 , 1999, Oncogene.
[42] S. Sen,et al. A putative serine/threonine kinase encoding gene BTAK on chromosome 20q13 is amplified and overexpressed in human breast cancer cell lines , 1997, Oncogene.
[43] Qing‐Yu He,et al. Proteomic analysis of a preneoplastic phenotype in ovarian surface epithelial cells derived from prophylactic oophorectomies. , 2005, Gynecologic oncology.
[44] B. Koller,et al. BRCA1 required for transcription-coupled repair of oxidative DNA damage. , 1998, Science.
[45] B. Werness,et al. Altered surface and cyst epithelium of ovaries removed prophylactically from women with a family history of ovarian cancer. , 1999, Human pathology.
[46] J. Swedlow,et al. Mitotic mechanics: the auroras come into view. , 2003, Current opinion in cell biology.
[47] Erich A Nigg,et al. Aurora kinases link chromosome segregation and cell division to cancer susceptibility. , 2004, Current opinion in genetics & development.
[48] D. Bell,et al. Origins and molecular pathology of ovarian cancer , 2005, Modern Pathology.
[49] N. Shao,et al. The second BRCT domain of BRCA1 proteins interacts with p53 and stimulates transcription from the p21WAF1/CIP1 promoter , 1999, Oncogene.
[50] P. V. van Diest,et al. Expression of differentiation and proliferation related proteins in epithelium of prophylactically removed ovaries from women with a hereditary female adnexal cancer predisposition , 2003, Histopathology.
[51] L. Hsu,et al. Identification of a -Tubulin-binding Domain in BRCA11 , 2001 .
[52] R. White,et al. Identification of a gamma-tubulin-binding domain in BRCA1. , 2001, Cancer research.